Inositol treatment of obsessive-compulsive disorder

American Journal of Psychiatry

Volumn 153, Issue 9, 1996, Pages 1219-1221

  Fux, Mendel ^a   Levine, Joseph ^a   Aviv, Alex ^a   Belmaker, R H ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b MENTAL HEALTH CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

INOSITOL; LORAZEPAM; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; MALE; OBSESSION; ORAL DRUG ADMINISTRATION; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND MESSENGER;

EID: 0029781472     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.9.1219     Document Type: Article

References (13)

1. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC: Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatry 1995; 52:53-60
2. Hoyter D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Sazena PR, Humphrey PPA: VII International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46:157-203
3. Rahman S, Neuman RS: Myo-inositol reduces serotonin (5-HT2) receptor induced homologous and heterologous desensitization. Brain Res 1993; 631:349-351
4. Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, Belmaker RH: Double-blind controlled trial of inositol treatment of depression. Am J Psychiatry 1995; 152:792-794
5. Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH: Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995; 152:1084-1086
6. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Gharney DS: The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006-1011
7. + ions. J Neurochemistry 1995; 65:2279-2289
8. Levine J, Rapaport A, Lev L, Bersudsky Y, Kofman O, Belmaker RH, Shapiro J, Agam G: Inositol treatment raises CSF inositol levels. Brain Res 1993; 627:168-170
9. Barak Y, Levine J, Glasman A, Elizur A, Belmaker RH: Inositol treatment of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 729-735
10. Levine J, Ring A, Barak Y, Elizur A, Belmaker RH: Inositol may worsen attention deficit disorder with hyperactivity. Hum Psychopharmacol 1995; 10:481-484
11. Levine J, Aviram A, Holan A, Ring A, Barak Y, Belmaker RH: Myo-inositol treatment of infantile autism: a double-blind placebo controlled trial. J Neural Transmission (in press)
12. Levine J, Goldberger I, Rapaport A, Schwartz M, Schields C, Elizur A, Belmaker RH, Shapiro J, Agam G: CSF inositol levels in schizophrenia are unchanged and inositol is not therapeutic in anergic schizophrenia. Eur Neuropsychopharmacol 1994; 4: 487-490
13. Kaplan Z, Amir M, Swartz M, Levine J: Inositol treatment of PTSD. Anxiety 1996; 2:51-52